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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 






23.02.2021 Signs and 
symptoms 
to determine 











(update to the 
July 2020 
review) 
• Based on currently 
available data, neither 
absence nor presence of 
signs or symptoms are 
accurate enough to rule in 
or rule out COVID-19 
• 44 relevant studies with 
26,884 participants were 
included. There were no 
studies specifically on 
children, and only one 
focussed on older adults 
• Most studies were 
conducted in hospital 
settings so results may not 
be representative of 
primary care settings. 
Results do not apply to 
children or older adults 
and do not differentiate 
between disease 
severities 
• A single symptom or sign 
cannot accurately 
diagnose COVID-19 but 
the presence of anosmia, 
ageusia, fever or cough, 
could be useful to identify 




• Prospective studies in an 
unselected population 
presenting to primary care 
or hospital outpatients 
settings, examining 
combinations of signs and 
symptoms to evaluate the 
syndromic presentation of 
COVID-19 remain urgent - 






















• Investigation of the 
existence and 
characterisation of clinical 
phenotypes for COVID-19 
patients at hospital 
admission 
• 3 distinct clinical 
phenotypes, based on 
demographics, underlying 
conditions, clinical and 
laboratory data and 
radiological features at 
presentation of patients 
admitted to hospital with 
COVID-19, were 
associated with patient 
prognosis and correlate 
with mortality 
• Authors have developed 
and validated a simplified 
probabilistic model for 
phenotype assignment 
available as a tool online  
• Identifying COVID-19 
phenotypes could allow 
better pathogenesis-
targeted approaches for 
therapies in the design 
and selection of 
participants in clinical trials 
and be helpful in clinical 
management by 
identifying low-risk 
patients and patients who 





























 bioRxiv | pre-
print (not peer 
reviewed) 
• Increased transmission of 
B.1.1.7 (VoC 202012/01) 
is not caused by 
increased replication (as 
measured on human 
airway epithelial cells) or 



















• Swift countrywide lockdowns 
enabled increased health 
system capacity but also 
resulted in economic 
hardship especially for the 
most vulnerable  
• During a health emergency, 
country leaders must 
maintain a unified front with 
continuous and accurate 
communication with the 
public to maintain trust with 
ongoing accountability 
among leaders and to avoid 
corruption 
• Epidemiological data is 
critical to inform types of 





• Healthcare workers and 
communities should be 




























receive oral or 
intravenous 
dexamethason
e for up to 10 
days (2104 




• Use of 
dexamethason






























• Evaluation of 
tocilizumab 
and sarilumab 

















in the intensive 
care unit 








































6 receptor, has 



























• Use of 
tocilizumab did 

























• Assessment of vaccine 
effectiveness for a range 
of outcomes in a diverse 
population in a 
noncontrolled setting – 
data from Israel’s largest 
health care organisation 
used to evaluate the 
effectiveness of the 
BNT162b2 mRNA 
vaccine 
• Newly vaccinated 
persons during the 
period 20 Dec 2020 to 1 
Feb 2021 were 
demographically and 









• Vaccine effectiveness 
was estimated for each 
of the following study 
outcomes at days 14 to 
20 after the first dose 
and at 7 or more days 





illness and death. Each 
study group included 
596.618 persons 
• This study in a 
nationwide mass 
vaccination setting 
suggests that the 
BNT162b2 mRNA 
vaccine is effective for a 
wide range of Covid-19 
related outcomes – 
consistent with 
randomised trial findings 

























• Telemedicine has been 
rapidly applied globally 
to address disruptions of 
healthcare provision 
during the COVID-19 
pandemic  
• Here the second round 
of a global online survey 
documents the 
experiences of providing 
telemedicine for 
maternal and newborn 




• Maternal and newborn 
healthcare providers 
globally considered 
telemedicine of benefit 




different components of 
maternal and newborn 
healthcare but rapid 
adaptation was not 
optimally supported by 
guidelines, training, 
adequate equipment, 
reimbursement for cost 
of connectivity and 
insurance payments for 
care provided remotely 
• Also, predominantly in 
LMICs, substantial 
groups of families were 
not able to be reached 
by telemedicine 
encountering different 
barriers in providing 
high-quality maternity 
care by 
telemedicine  including 
internet connection 
problems, lack of 
necessary equipment, 
digital illiteracy and 
distrust 
• Authors recommend that 
more research regarding 
the effectiveness, 
efficacy and quality of 
telemedicine for 
maternal healthcare in 
difference contexts is 
needed before long-term 
adaptations in care 
provision away from 
face-to-face interactions 
• Guidelines for care 
provision and 
approaches are need to 
minimise socioeconomic 
and technological 
inequalities in access to 
care  











• Analysis exploring the 
social and economic 
impact of, and 
responses to, COVID-19 
and how it is affecting 
























• International human 
rights law requires that 
if ‘vulnerability’ is used 
as a criterion for 
priority access to 
COVID-19 vaccines, 
this must include social 
vulnerability (e.g. 
socioeconomic status) 




of intersectional needs 
in society and the 
disproportionate impact 
that COVID-19 is 
having on population 
groups with pre-
existing social and 
medical vulnerabilities 
• Here authors state that 
existing 
frameworks/mechanis
ms and proposals for 
COVID-19 vaccine 
allocation have 





needing to adopt a 
more intersectional 
approach allocating 
COVID-19 vaccines on 
health, social and 
financial 









Comments, Editorials, Opinions, Blogs, News 
 Publication 
date 
Title/URL Journal | Article type 
01.03.2021 Supporting COVID-19 Recovery and Improving 
Health Outcomes: The Case for Health Taxes 
CGD | Blog 
March 2021 Feelings towards COVID-19 vaccination in Africa The Lancet Infection 
Diseases | Newsdesk 
March 2021 COVID-19 hindering progress against female 
genital mutilation 
The Lancet Public Health | 
Editorial 
March 2021 Migrant health is public health: a call for equitable 
access to COVID-19 vaccines 
The Lancet Public Health | 
Correspondence 
01.03.2021 COVID-19 research in critical care: the good, the 
bad, and the ugly 
Intensive Care Medicine 
01.03.2021 India’s COVID-19 vaccine roll-out in a nutshell Southern Voice | Blog 
27.02.2021 New WTO leader faces COVID-19 challenges The Lancet | World Report 
27.02.2021 Just allocation of COVID-19 vaccines BMJ Global Health | 
Editorial 
27.02.2021 FDA Issues Emergency Use Authroization for third 
COVID-19 Vaccine 
FDA | News 
26.02.2021 An expert explains variants  Wellcome | News 
25.02.2021 Interleukin-6 Reception Inhibition in Covid-19 – 
cooling the inflammatory soup 
NEJM | Editorial 
25.02.2021 Research in the context of a pandemic NEJM | Editorial 
25.02.2021 The RECOVERY Platform NEJM | Editorial 
24.02.2021 Major rise in public support for COVID vaccine – 
Oxford study 
Oxford University | News 
24.02.2021 COVID-19 drug practices risk antimicrobial 
resistance evolution 
The Lancet Microbe 
23.02.2021 Who gets a COVID-19 vaccine and who pays? 
The need for economic analysis 
CGD | Blog 
19.02.2021 Creating effective research-policy partnerships for 
COVID response and beyond 
CGD | Blog 
02.02.2021 Comparing the Covid-19 vaccines developed by 
Pfizer, Moderna, and Johnson & Johnson 
STAT | News 
   
 
Dashboards & Trackers  












  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  


















Nigeria CDC  Norwegian 
Institute of Public 
Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford Vaccine 
Trial 





US NIH   Our World in 
Data: C19 
Testing 





Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence      Our World in 
Data: COVID-
19 vaccinations  
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 




  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
   
 
C19 Resource Hubs 
 
















































































Direct C19 blog 
series 



















Institute of Public 
Health 
    






Oxford Centre for 
Evidence-based 
Medicine 
    
UNICEF   The Lancet  HEART     




 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
University 
Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources 
and Analyses of 
C19 Impact 
    




    
Our World in 
Data 





  Springer 
Nature 
      
Reliefweb   SSRN 
(Preprints)  













      
WorldPop           
Flowminder           





    
  
GISAID           
Online learning & events 






Diseases in the 
COVID era 





for health workers 
Online training 3h  WHO 
14.01.2021 Evidence to impact in 
crisis: how have we 
measured up during 
the COVID-19 
pandemic? 
Webinar 1h 30 CGD 
04.12.2020 COVID-19, supply 
chain resilience and 
global trade 
Webinar 1h CGD 
03.12.2020 More money for 
health services: What 
is the tole of PFM in 
the “new normal”? 




1h 30 Joe Kutzin 
01.12.2020 Solutions and support 
for the mental 
wellbeing of 
community health 
workers on the 
COVID-19 frontline 
Webinar   HSG TWG on CHWs 
with The George 
Institute for Global 
Health 
19.11.2020 Looking at the 




  SSHAP 
16.11.2020 HIFA and WHO 
collaborate to 
promote sharing of 
experience and 
expertise around the 
maintenance of 
essential health 
services during (and 
after) the pandemic 
4-week 
discussion 
starting 16 Nov 
  HIFA 
10.11.2020 COVID-19 vaccine 
predictions part 2: 
estimating the time 
before we approve 
efficacious COVID-19 
vaccines 
Online event 1h30 CGD 
16.10.2020 Financing a Global 
Public Health 
Response 
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the 
Economic and Health 
Impact of COVID-19 
across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
emergencies, now 
offers 10 online 
courses related to 
COVID19. 












Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours 
per week 




WHO Academy and 
WHO Info mobile 
applications 





Modelling and Policy 









11.5.2020 COVID-19 Contact 
Tracing course 
Online learning 5 hours Johns Hopkins 






5 sessions 1h 30 International Initiative 












online brief with Dr 
David Nabarro 














training for the 
coronavirus disease 
outbreak 

































6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 





of Edinburgh & Royal 
College of Physicians 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary 
research papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease 
control and health system responses are included. Articles related to tackling the secondary impacts on other 
sectors are not included. Additional commentaries, opinions, and commissioned pieces are selected based on 
relevance. 
  
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
  
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
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